- Home
- IMMP vs AQST Comparison
IMMP vs AQST Comparison
Compare IMMP & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- AQST
- Stock Information
- Founded
- IMMP 1987
- AQST 2004
- Country
- IMMP Australia
- AQST United States
- Employees
- IMMP N/A
- AQST 135
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- IMMP Health Care
- AQST Health Care
- Exchange
- IMMP Nasdaq
- AQST Nasdaq
- Market Cap
- IMMP 304.0M
- AQST 274.4M
- IPO Year
- IMMP N/A
- AQST 2018
- Fundamental
- Price
- IMMP $1.92
- AQST $3.01
- Analyst Decision
- IMMP Buy
- AQST Strong Buy
- Analyst Count
- IMMP 2
- AQST 8
- Target Price
- IMMP $8.50
- AQST $10.38
- AVG Volume (30 Days)
- IMMP 72.2K
- AQST 2.0M
- Earning Date
- IMMP 03-03-2025
- AQST 03-05-2025
- Dividend Yield
- IMMP N/A
- AQST N/A
- EPS Growth
- IMMP N/A
- AQST N/A
- EPS
- IMMP N/A
- AQST N/A
- Revenue
- IMMP $2,563,302.00
- AQST $58,900,000.00
- Revenue This Year
- IMMP N/A
- AQST $18.44
- Revenue Next Year
- IMMP $47.79
- AQST N/A
- P/E Ratio
- IMMP N/A
- AQST N/A
- Revenue Growth
- IMMP 9.59
- AQST 22.56
- 52 Week Low
- IMMP $1.66
- AQST $2.24
- 52 Week High
- IMMP $3.34
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- IMMP 43.56
- AQST 43.29
- Support Level
- IMMP $1.94
- AQST $2.95
- Resistance Level
- IMMP $2.08
- AQST $3.21
- Average True Range (ATR)
- IMMP 0.08
- AQST 0.20
- MACD
- IMMP -0.00
- AQST 0.02
- Stochastic Oscillator
- IMMP 20.00
- AQST 18.42
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.